How Pf-07304814 Turned a Solubility-limited Inhibitor Into an Iv Candidate
PF-00835231 potently inhibits the SARS-CoV-2 main protease, but low aqueous solubility, limited oral bioavailability, and a short projected half-life restricted its dosing options. Continuous intravenous infusion could provide minimum target exposure, yet higher doses required impractical volumes. Researchers therefore converted it into a phosphate prodrug.
From active inhibitor to soluble prodrug
Researchers created PF-07304814, later named lufotrelvir, by converting the primary alcohol of PF-00835231 into a phosphate ester. This increased aqueous solubility to more than 200 mg/mL, allowing relevant doses to be delivered in a manageable infusion volume. Alkaline phosphatase removes the group in vivo and releases PF-00835231.
Why weaker enzyme potency is expected
PF-07304814 inhibited SARS-CoV-2 3CLpro with a reported Ki of 174 nM, more than 600-fold weaker than the 0.27 nM Ki of PF-00835231. This confirms that the prodrug is not intended to provide most antiviral activity before conversion.
Cellular assays can blur the distinction because phosphatases convert the prodrug during incubation. In one three-day Vero E6 assay, PF-00835231 reached about half the starting prodrug concentration. Biochemical potency comparisons should therefore use the active parent, while PF-07304814 is more informative for delivery, conversion, and pharmacokinetic studies.
What conversion studies confirmed
Intravenous studies in rats, dogs, and monkeys produced PF-00835231 exposures equivalent to 68% to 81% conversion, averaging about 75%. Modeling predicted a prodrug half-life of about 0.1 hour and rapid formation of the active moiety.
Clinical studies confirmed PF-00835231 formation during infusion. In healthy adults, 24-hour infusions of 50, 150, 500, or 700 mg caused no serious adverse events, discontinuations, or deaths. A Phase 1b study enrolled 26 hospitalized participants and evaluated 250- or 500-mg infusions over 24 or 120 hours. Treatment was generally well tolerated, but efficacy was not assessed.
Why infusion remained a limitation
Coronavirus 3CLpro is conserved and has no close human counterpart, supporting selective antiviral development. Continuous infusion, however, confines treatment largely to monitored settings and is less suitable for early outpatient use than an oral drug.
Evidence does not establish infusion as the sole reason lufotrelvir was not advanced further. It does explain why orally bioavailable Mpro inhibitors offered a major practical advantage as COVID-19 treatment shifted toward early intervention.
PF-07304814 remains a useful example of phosphate-prodrug design. It converted a poorly soluble inhibitor into an IV-compatible candidate, and its research value lies in documented solubility, conversion, and clinical pharmacokinetics rather than direct enzyme potency.
